Genome and transcriptome sequencing in prospective metastatic triple-negative breast cancer uncovers therapeutic vulnerabilities. - Wikidata - awgldk - TriplyDB

Genome and transcriptome sequencing in prospective metastatic triple-negative breast cancer uncovers therapeutic vulnerabilities.

Genome and transcriptome sequencing in prospective metastatic triple-negative breast cancer uncovers therapeutic vulnerabilities.

http://www.wikidata.org/entity/Q39516141

about

Characterization of X chromosome inactivation using integrated analysis of whole-exome and mRNA sequencing A pilot study using next-generation sequencing in advanced cancers: feasibility and challenges Current Management Strategies in Breast Cancer by Targeting Key Altered Molecular Players The Role of Forkhead Box Protein M1 in Breast Cancer Progression and Resistance to Therapy Somatic mutations in breast and serous ovarian cancer young patients: a systematic review and meta-analysis Circulating Tumor Cells: A Window Into Tumor Development and Therapeutic Effectiveness Molecular Technologies in the Clinical Diagnostic Laboratory Status of PI3K/Akt/mTOR pathway inhibitors in lymphoma Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine.Personalized treatment of Sézary syndrome by targeting a novel CTLA4:CD28 fusion.Novel therapeutic strategies for patients with triple-negative breast cancer Prospective molecular profiling of canine cancers provides a clinically relevant comparative model for evaluating personalized medicine (PMed) trials Development of a RSK Inhibitor as a Novel Therapy for Triple-Negative Breast Cancer.A thirteen-gene expression signature predicts survival of patients with pancreatic cancer and identifies new genes of interest.Wnt signaling in triple negative breast cancer is associated with metastasis Bayesian methods for expression-based integration of various types of genomics data.Review of current methods, applications, and data management for the bioinformatics analysis of whole exome sequencing.Regulators associated with clinical outcomes revealed by DNA methylation data in breast cancer.Data Interoperability of Whole Exome Sequencing (WES) Based Mutational Burden Estimates from Different Laboratories Targeting oncogenic vulnerabilities in triple negative breast cancer: biological bases and ongoing clinical studies.Circulating Tumor DNA Mutation Profiling by Targeted Next Generation Sequencing Provides Guidance for Personalized Treatments in Multiple Cancer Types Integrated analysis of recurrent properties of cancer genes to identify novel drivers Pathway-based analysis of breast cancer.Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease.Increased risk of brain metastases in women with breast cancer and p16 expression in metastatic lymph-nodes α-catenin. A tumor suppressor beyond adherens junctions.Novel role of Engrailed 1 as a prosurvival transcription factor in basal-like breast cancer and engineering of interference peptides block its oncogenic function.Translating RNA sequencing into clinical diagnostics: opportunities and challenges.Mutational profiles in triple-negative breast cancer defined by ultradeep multigene sequencing show high rates of PI3K pathway alterations and clinically relevant entity subgroup specific differences.Pharmacological profiling of kinase dependency in cell lines across triple-negative breast cancer subtypes.Triple negative breast tumors in African-American and Hispanic/Latina women are high in CD44+, low in CD24+, and have loss of PTEN.Whole genome sequencing reveals potential targets for therapy in patients with refractory KRAS mutated metastatic colorectal cancer.Revealing the Molecular Portrait of Triple Negative Breast Tumors in an Understudied Population through Omics Analysis of Formalin-Fixed and Paraffin-Embedded Tissues.Molecular heterogeneity in adjacent cells in triple-negative breast cancer.Evaluation and integration of cancer gene classifiers: identification and ranking of plausible drivers.Discovery and functional characterization of a neomorphic PTEN mutation.Capture-based next-generation sequencing reveals multiple actionable mutations in cancer patients failed in traditional testing.Development and clinical application of an integrative genomic approach to personalized cancer therapy Novel insights into breast cancer genetic variance through RNA sequencing.

P2860

Q21131890-D249F003-189C-4928-A654-E99E5C7CFE54 Q21132483-75C0D275-77EA-4643-8FC3-63D4ABD54E35 Q26765877-AC5D3DE7-8888-4BCD-BC83-CED0E83325CD Q26768290-2B833BA7-02F3-40F5-8062-3B10809B21BC Q26776018-AF6CB661-8059-4973-8047-10BE44B49269 Q26827815-D3D06811-6A82-4424-A5E6-14275FB3A8DB Q26996463-E2AA2FAF-59C8-4436-B7E3-E0B00D6C60E0 Q27026544-A476AC64-7B47-4CE7-86DC-3798656C6DB5 Q27852856-D8781D70-4702-4313-91C3-062C7D61F15A Q27853005-74CE34AE-ABB9-48FE-B57B-5D24529C2C24 Q27853146-6CDA2349-66AB-4F9F-AC75-0661ED5C87F9 Q28067436-97348491-99C3-4CE2-ACDE-C6DF9F42CB87 Q28540955-F14A8CED-5417-40D0-A06D-384B07E075A3 Q30275521-FDEA1B86-10A9-4887-A33A-01E48C504E10 Q30410836-102E2692-C0C0-4B29-B88E-980E5D9FE484 Q30597238-2F14E1E4-C177-4D27-BED9-31310726C093 Q30668548-E3C7FD00-B9F0-48B4-A8E7-E1CD924A0D63 Q30857788-18DFD77B-046C-4966-BD63-584CCA7D6319 Q30956005-62355A7B-4B5C-4612-AB89-AACCCDEEFC2C Q31089220-22AB567A-F904-4C2C-B4CC-8E67623F51E2 Q33591876-72257140-020D-4D6A-8601-566D7FBF2A4C Q33673752-92473CFD-8726-459E-AB2D-AB4BC45A4F68 Q33742981-415EB2CF-AB3D-42BB-AFAB-320EBED62311 Q33758011-774F5D4E-4465-44EF-B800-51C3CA729E93 Q33769821-3B77427D-3C45-48F1-97F2-E64C67153083 Q33913936-F34662A1-16A4-48DC-8253-2DF1D4A8E4A6 Q34028517-E4262791-FF04-4836-9B89-19860192BBEF Q34285190-6588FC9D-74F8-4B7E-B541-1AD611D6CEA4 Q34519034-9A6921A0-23C9-4448-93D9-BB454AECDE7A Q34654793-5C5AF34F-3E06-4F32-B66F-0E1E2E9E3CE8 Q34978420-043FC467-6128-4DAE-BED4-089CA9D7CB73 Q35027892-8730BCBD-32A2-428E-A05F-CE5E086F76C7 Q35190834-8D976DDA-F3F9-46C3-BD11-71A7BF09FBC6 Q35593154-A14BC2ED-0F8C-48E6-B6EC-615827CD766A Q35965925-1A0D4A56-D4BF-4978-8D12-15F8631B32A7 Q36294122-F5026789-206F-46B8-8778-434D3531E832 Q36300265-3989A99E-0089-4B4C-A139-B34D8432B876 Q36902969-79183442-0389-412F-B466-8F9A11FEB9EA Q36954557-DD74D39B-5D1C-4F38-B6CB-C177B2ABA0AD Q37043550-2EC0D596-1402-488D-92B3-162FA6F7DAF4

P2860

Genome and transcriptome sequencing in prospective metastatic triple-negative breast cancer uncovers therapeutic vulnerabilities.

http://www.wikidata.org/entity/Q39516141

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Genome and transcriptome seque ...... s therapeutic vulnerabilities.

@en

Genome and transcriptome seque ...... s therapeutic vulnerabilities.

@nl

type

label

Genome and transcriptome seque ...... s therapeutic vulnerabilities.

@en

Genome and transcriptome seque ...... s therapeutic vulnerabilities.

@nl

prefLabel

Genome and transcriptome seque ...... s therapeutic vulnerabilities.

@en

Genome and transcriptome seque ...... s therapeutic vulnerabilities.

@nl

P1433

Q39516141-689FD6B1-19CA-46F1-B48F-8AAB666F5D04

P1476

Q39516141-F28CB354-1752-4578-8476-20F53CAC3869

P2093

Q39516141-114C0196-6794-47D5-886F-B0923C692E35

Q39516141-2A92EAA2-8B0E-4571-B118-2E97E4BA106B

Q39516141-308B0C6F-06E2-43F3-AB8C-5330E3242041

Q39516141-3EB8B1FD-48D6-479D-82F8-2BB920118571

Q39516141-421A2790-932F-439E-B5DF-F67FB7032C2F

Q39516141-43150F33-8F92-4921-9521-B2C955F5B2BB

Q39516141-5887A1CA-BBD4-426B-8F24-17BD57DBC0B2

Q39516141-5F5A5E86-F239-4576-98D0-F9129A8C8AE8

Q39516141-61C235B4-BCA4-45D8-9349-8E4E9B28E5B0

Q39516141-77DA9843-C510-4875-A447-1DD75E8BB994

P304

Q39516141-3012E7AE-5391-46DA-B2B4-D2867BBB9F7B

P31

Q39516141-33FDE3BB-E0C5-4DD2-A254-9F49D70EF397

P356

Q39516141-99D666FA-CD5D-4B55-AD8E-8F119CDCAC18

P433

Q39516141-0429A189-2A8D-4309-8307-9F4D840BD4DE

P478

Q39516141-E17A61AD-05DF-47CA-B26D-EB2E9D0BFB5B

P577

Q39516141-A0119E00-F50F-416B-81C9-9AC332F1D15C

P698

Q39516141-C0C647AA-F014-47B8-88B4-EBAF711723C8

P921

Q39516141-919FBE5D-56AA-4728-A367-854B55C01A32

P356

1535-7163.MCT-12-0781

P1433

Molecular Cancer Therapeutics

P1476

Genome and transcriptome seque ...... s therapeutic vulnerabilities.

@en

P2093

Ahmet Kurdoglu

http://www.w3.org/2001/XMLSchema#string

Alexis Christoforides

http://www.w3.org/2001/XMLSchema#string

Angela Baker

http://www.w3.org/2001/XMLSchema#string

Anthony W Tolcher

http://www.w3.org/2001/XMLSchema#string

Asim Siddiqui

http://www.w3.org/2001/XMLSchema#string

Bodour Salhia

http://www.w3.org/2001/XMLSchema#string

Catalin Barbacioru

http://www.w3.org/2001/XMLSchema#string

Cristi L Aitelli

http://www.w3.org/2001/XMLSchema#string

Cynthia R Osborne

http://www.w3.org/2001/XMLSchema#string

Daniel Von Hoff

http://www.w3.org/2001/XMLSchema#string

P304

104-116

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1535-7163.MCT-12-0781

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P577

2012-11-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23171949

http://www.w3.org/2001/XMLSchema#string

P921